This study focuses on individuals with metastatic non-small cell lung cancer, a type of lung cancer that has spread to other parts of the body. The purpose of the study is to evaluate the safety and effectiveness of combining new cancer treatments. The medications being studied include ramucirumab, which is also known as Cyramza, and a new drug called rilvegostomig. These medications are administered through intravenous infusion, which means they are delivered directly into a vein.

The research is conducted in different stages to carefully monitor how the body reacts to these drug combinations. Initially, the focus is on determining the safest and most appropriate amount of medicine to give. Following this, the study expands to observe how well these combinations work in shrinking tumors. During the study, medical professionals will monitor various health indicators, such as vital signs and laboratory results, to ensure safety throughout the process.